Through metabolomic and transcriptomic analyses, a glutamine‐enriched, immunosuppressive microenvironment is identified in cervical squamous cell carcinoma (CSCC), highlighting the glutamine transporter SLC25A22 as a key regulator of glutamine metabolism, immune checkpoint activation, and CD8+ T‐cell cytotoxicity. The gene discussed is SLC25A22; the disease is skin squamous cell carcinoma.